Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04692324 · ClinicalTrials.gov registry record
Cerebrospinal Fluid Biomarkers for Brain Tumors
A clinical trial of Central Nervous System Neoplasm, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT04692324 is a study of Central Nervous System Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 300 participants, below the 10,798-participant average among 7 other Central Nervous System Neoplasm trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04692324, a study of Central Nervous System Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines cerebrospinal biomarkers in patients with brain tumors. A biomarker is a measurable indicator of the severity or presence of your disease state. Collecting and storing samples of cerebrospinal fluid from patients with brain tumors to study in the laboratory may help doctors develop new strategies to better diagnose, monitor, and treat brain tumors.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Survey Administration
- OTHER Electronic Health Record Review
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-01-14 |
| Est. Completion | 2028-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04692324
The ClinicalTrials.gov registry entry for NCT04692324 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 10,798-participant average among 7 other Central Nervous System Neoplasm trials with a reported enrollment target (97% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Nervous System Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT04692324 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04692324 about?
NCT04692324 is a clinical study titled "Cerebrospinal Fluid Biomarkers for Brain Tumors". This study examines cerebrospinal biomarkers in patients with brain tumors. A biomarker is a measurable indicator of the severity or presence of your disease state. Collecting and storing samples of cerebrospinal fluid from patients with brain tumors to study in the laboratory may help doctors devel...
What is the current status of trial NCT04692324?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2021-01-14. Estimated completion is 2028-12-31.
What conditions does trial NCT04692324 study?
This clinical trial studies the following conditions: Central Nervous System Neoplasm.
What interventions are being tested in trial NCT04692324?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Survey Administration (OTHER), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT04692324?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04692324 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology
RECRUITING
-
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
RECRUITING · Phase 2
-
Project: Every Child for Younger Patients With Cancer
RECRUITING
-
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.